Figure 4From: Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies FEV 1 0–4 h after initial dose – GMAD study COPD patients. Back to article page